Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): A compound according to formula (I) ~~hereinbelow~~:



(I)

wherein:

R_1 represents NR_4R_5;

R_2 represents $CONH_2$ or SO_2NH_2;

R_3 represents up to three substituents selected from the group consisting of halogen, C_{1-4}alkyl, NH_2, CF_3, OCF_3, O-alkyl, S-alkyl, CN, CHO, SO_2-alkyl, and NO_2;

R_4 represents H[[,]] or C_{1-2} alkyl;

R_5 represents $C(=A)NHR_6$, COR_7, or R_6;

A represents O, S, or N;

R_6 represents H, or C_{1-2} alkyl;

R_7 represents C_{1-2} alkyl; and

L represents a linker D-E-D such that

D represents a bond or C_{1-4} alkyl;

E represents  ; and

G and I independently represent H[[,]] or C_{1-2} alkyl; or a ~~pharamceutically~~ pharmaceutically acceptable salt thereof, provided that the compound of formula (I) is not 2-[(aminocarbonyl)amino]-5-{[(4-chlorophenyl)methyl]oxyl-3-thiophenecarboxamide.

2. (Original): A compound according to claim 1 wherein R_2 is $CONH_2$.

3. (Original): A compound according to claim 1 wherein R_5 is $C(=A)NHR_6$.

4. (Original): A compound according to claim 1 wherein A is O.

5. (Original): A compound according to claim 1 wherein E is

C = C, CONH, or .

6. (Currently amended): A compound according to claim 1 wherein the compound is selected from the group consisting of:
5-[(E)-phenyl)-ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;
5-[(E)-2-(4-Fluoro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acidamide;
5-[(E)-2-(4-Chloro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;
5-Phenethyl-2-ureido-thiophene-3-carboxylic acid amide;
5-Benzyl-2-ureido-thiophene-3-carboxylic acid amide;
5-(1-Phenyl-ethyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-Phenylethynyl-2-ureido-thiophene-3-carboxylic acid amide;
5-(4-Fluorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-(4-Ethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-(4-Methoxyphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-(4-Chlorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide[[ ]];
5-(4-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-(3-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide; and
5-Acetylamino-thiophene-2,4-dicarboxylic acid 4-amide 2-[(3-chloro-phenyl)-amide]; or a pharmaceutically acceptable salt thereof.

7. (Original): A method of treating a disease characterized by pathological NF-κB activation comprising inhibiting the pathological activation by administering to a patient in need thereof an effective amount of a compound according to claim 1.

8. (Original): A method according to claim 7 wherein the disease is an inflammatory or tissue repair disorder.

9. (Currently amended): A method according to Claim 8 wherein the disease is ~~selected from the group consisting of~~ an inflammatory ~~and~~ or tissue repair disorder ~~disorders, particularly~~ selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, asthma, [[and]] COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis, [[and]] fibrotic disease ~~diseases~~, dermatosis, ~~including~~ psoriasis, atopic dermatitis, [[and]] ultraviolet radiation (UV)-induced skin damage, ~~autoimmune diseases including~~ systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue rejection, [[and]] organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, ~~including~~ Hodgkins disease, cachexia, inflammation associated with infection, ~~and certain viral infections, including~~ ~~aquired~~ inflammation associated with acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiestasia.

10. (Original): A method according to claim 7 wherein said disease is COPD.

11. (Original): A method according to claim 7 wherein said disease is asthma.

12. (Original): A method according to claim 7 wherein said disease is rheumatoid arthritis.

13. (Original): A method according to claim 7 wherein said disease is dermatosis.

14. (Original): A method according to claim 7 wherein the disease is selected from the group consisting of: psoriasis, atopic dermatitis, and UV-induced skin damage.

15. (Currently amended): A method according to claim 7 wherein the disease is selected from the group consisting of ~~autoimmune diseases;~~ tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, osteoarthritis, osteoporosis, and Ataxia Telangiestasia.

16. (Canceled).

17. (Currently amended): A method according to claim [[9]] 7 wherein the ~~autoimmune~~ disease is systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, [[or]] alkylosing spondylitis, or diabetes.

18. (Currently amended): A method according to claim 7 wherein the disease is cancer [[and]] or cachexia.

19. (Original): A method according to claim 7 wherein the cancer is Hodgkins disease.

20. (Currently amended): A method according to claim 7 wherein the disease is inflammation associated with infection ~~and certain viral infections, including~~ and acquired immune deficiency syndrome (AIDS).

21. (Original): A method according to claim 7 wherein the disease is AIDS.

22. (Original): A method according to claim 7 wherein the disease is adult respiratory distress syndrome.

23. (New): A compound according to claim 1 wherein E is



.

24. (New): A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.